10 August 2024
Latham & Watkins Advises Zevra on Public Offering of Common Stock
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Salvatore Vanchieri Lead | Latham & Watkins LLP | Partner | capital markets | New York |
| Angel Marcial | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Yulong Li | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Elizabeth Richards | Latham & Watkins LLP | Not stated | FDA regulatory matters | Not stated |
Stated terms
- Stated value
- USD 60m (approximately US$60 million)
- What the figure measures
- Issue size
- Client
- Zevra Therapeutics, Inc.Issuer
- Counterparties
- Not stated